Prostate cancer
Personalising care for patients with biochemical recurrence

Case 1: Henrique

Henrique, 70 years old, has a history of PCa.

Assessment summary:

  • Medical history: well-controlled hypertension, diagnosis of intermediate-risk PCa 5 years ago:
  • PSA: 11 ng/ml
  • DRE: cT2a
  • mpMRI: PI-RADS 4 lesion lateral left, no extracapsular extension, prostate volume 40 ml
  • Prostate biopsy: ISUP grade group 3 (Gleason 4+3)
  • Bone scan and CT scan: N0M0
  • Underwent RP + ePLND, pathology findings:
  • pT2, ISUP grade group 3 (Gleason 4+3)
  • Negative surgical margins
  • Postoperative PSA: undetectable, last undetectable PSA 28 mo ago
  • Diagnostic work-up today:
    • PSA is slowly rising
      • 24 months ago: 0.10 ng/ml
      • 21 months ago: 0.12 ng/ml
      • 18 months ago: 0.11 ng/ml
      • 12 months ago: 0.15 ng/ml
      • Today: 0.23 ng/ml
    • PSA doubling time: 20 months
    • ECOG PS: 0

Which of the following treatment options would you choose for this patient?